High-risk pulmonary embolism in a post-COVID 19 female under hormonal contraception

Andrea Sonaglioni 1*, Michele Lombardo 1, Adriana Albini 2, and Sergio Harari 3

1Department of Cardiology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Via San Vittore 12, 20123 Milan, Italy; 2Scientific Directorate, European Institute of Oncology (IEO) Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy; and 3Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy

Received 17 July 2023; revised 18 October 2023; accepted 3 November 2023; online publish-ahead-of-print 6 November 2023

A 29-year-old, nulliparous, non-smoker, overweight (body surface area 1.97 m²; body mass index 29.4 kg/m²) female presented to the emergency room of our hospital for ongoing dyspnoea, tachycardia, and general malaise. She had a recent COVID-19 infection, presenting with mild symptoms (pharyngodynia only), which occurred 4 weeks before and lasted 1 week. Moreover, she had a history of chronic oral contraceptive pill (OCP, levonorgestrel 0.10 mg and ethinylestradiol 0.02 mg daily) use for 6 years. At hospital admission, blood pressure was 90/60 mmHg, heart rate was 132 b.p.m., arterial oxygen saturation was 88%, and body temperature was 36.5°C. Arterial blood gas analysis showed hypocapnia (pCO₂ 27.6 mmHg) and hypoaemia (pO₂ 66 mmHg) with mild respiratory alkalosis (pH 7.48). The electrocardiogram revealed sinus rhythm with an S1Q3T3 pattern (Figure 1A). A bedside transthoracic echocardiography (TTE) showed saddle pulmonary embolism (PE, Figure 1B), with McConnell’s sign (right ventricular free wall akinesis with sparing of the apex) due to severe pulmonary hypertension (tricuspid regurgitation velocity > 3.4 m/s). An urgent computed tomography (CT) pulmonary angiography confirmed extensive saddle PE (Figure 1C). Computed tomography venography documented concurrent thrombosis of the left saphenofemoral junction and great saphenous vein (Figure 1D). The estimated Pulmonary Embolism Severity Index score was 119 (Class IV, high 30-day mortality risk, 4.0–11.4%). Accordingly, the patient underwent systemic thrombolysis with a recombinant tissue plasminogen activator (rtPA) 100 mg infusion over 2 h, followed by enoxaparin sodium 6000 IU subcutaneously twice daily. After treatment, she showed a rapid improvement in her haemodynamic and ventilatory patterns, the electrocardiogram quickly normalized, and saddle PE disappeared on TTE (Figure 1E). The further use of OCP was contraindicated, and, on Day 6 after presentation, the patient was discharged from our institution with the indication of 6 months of anticoagulant therapy with apixaban 5 mg twice a day.

To date, only two authors have described the association between chronic OCP use and venous thromboembolism/PE in the acute phase of COVID-19 disease.1,2 Differently from these authors who reported segmental or subsegmental cases of PE in acute COVID-19 patients, we described a case of proximal PE detected during the post-acute phase of COVID-19 disease. Given that during the convalescent phase of COVID-19 disease, a state of endothelial dysfunction, hypercoagulability, and low-grade inflammation may be persistent,1,4 it is likely that OCP may have exerted an additive prothrombotic effect on a substrate of chronic immuno-thrombogenicity related to COVID-19 infection.

Acknowledgements

This work has been supported by the Italian Ministry of Health Ricerca Corrente—IRCCS MultiMedica.

Consent: The authors confirm that witnessed verbal consent for submission and publication of this case report including images and associated text has been obtained from the patient detailed in this case report. This has been discussed with the editors.

Ethics approval: This study was conducted in accordance with the World Medical Association Declaration of Helsinki. The local ethics committee decided that ethics approval was not required in a single-case image. No personal identifying information was included in this manuscript.

Conflict of interest: None declared.

Funding: None declared.

* Corresponding author. Tel: +39 0285994276, Email: sonaglioniandrea@gmail.com
Handling Editor: Rita Pavasini
Peer-reviewers: Suzan Hatipoglu and Gautam Sen
© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.
Data availability
The data underlying this article will be shared upon reasonable request to the corresponding author.

References